Travis Steed
Stock Analyst at Barclays
(2.86)
# 1,578
Out of 4,829 analysts
85
Total ratings
45.59%
Success rate
6.78%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $167.22 | +56.08% | 8 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $297.32 | +7.63% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $133.24 | +12.58% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $70.23 | +21.03% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $73.68 | +22.15% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $15.97 | +100.38% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $30.90 | +45.63% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $15.08 | +198.41% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $380.92 | -17.31% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $310.67 | -5.04% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $11.37 | +40.78% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $22.98 | +43.60% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $95.21 | +68.05% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $536.51 | -41.29% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $3.37 | +137.39% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $11.97 | +108.86% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.45 | +488.24% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $84.67 | +47.63% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $83.48 | +73.69% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $102.86 | -50.42% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $57.08 | +206.59% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $12.25 | +340.82% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $81.74 | -73.09% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $167.22
Upside: +56.08%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $297.32
Upside: +7.63%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $133.24
Upside: +12.58%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $70.23
Upside: +21.03%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $73.68
Upside: +22.15%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $15.97
Upside: +100.38%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $30.90
Upside: +45.63%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $15.08
Upside: +198.41%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $380.92
Upside: -17.31%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $310.67
Upside: -5.04%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $11.37
Upside: +40.78%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $22.98
Upside: +43.60%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $95.21
Upside: +68.05%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $536.51
Upside: -41.29%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $3.37
Upside: +137.39%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $11.97
Upside: +108.86%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.45
Upside: +488.24%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $84.67
Upside: +47.63%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $83.48
Upside: +73.69%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $102.86
Upside: -50.42%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $57.08
Upside: +206.59%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $12.25
Upside: +340.82%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $81.74
Upside: -73.09%